Patent No. EP3760715 (titled "Large-Scale Production Of Soluble Hyaluronidase") was filed by Halozyme on Mar 6, 2009. The application was issued on Aug 4, 2021.
A harvested cell culture fluid, separated from cells, debris, and aggregates, comprises soluble recombinant human PH20 (rHuPH20) expressed in Chinese Hamster Ovary (CHO) cells. The rHuPH20 polypeptide comprises the sequence of SEQ ID NO: 4 or a variant with $\ge$96% sequence identity. The fluid exhibits hyaluronidase enzymatic activity between >5,000 and $\le$24,000 units/mL. Activity is determined by incubating rHuPH20 with sodium hyaluronate for 10 minutes, precipitating undigested hyaluronate with acidified serum albumin, measuring turbidity at 640 nm after a 30-minute development period, and comparing results against a soluble rHuPH20 assay working reference standard calibration curve. The fluid is produced via large-scale bioreactor cultures using specific sequential feed media and temperature shifts to optimize synthesis and cell viability.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description